DLL3 (delta-like ligand 3) is a Notch signaling pathway inhibitor that plays critical roles in neurogenesis and somitogenesis, while serving as a promising therapeutic target in neuroendocrine malignancies. The protein functions as an inhibitory Notch ligand that is highly expressed in small cell lung cancer (SCLC) and other neuroendocrine tumors but minimally expressed in normal adult tissues 12. DLL3's aberrant expression is associated with tumorigenesis and poor clinical outcomes, particularly in neuroendocrine carcinomas 2. Mechanistically, DLL3 overexpression on tumor cell surfaces makes it an ideal target for novel immunotherapies 3. This has led to the development of multiple DLL3-targeted therapeutic approaches, including bispecific T-cell engagers like tarlatamab, which demonstrated a 23.4% objective response rate in heavily pretreated SCLC patients 4, and CAR-T cell therapies that show enhanced efficacy when modified to secrete IL-18 5. The clinical significance of DLL3 extends beyond SCLC, as it represents a broadly actionable target across neuroendocrine neoplasms where current treatments provide limited sustained responses 2. These DLL3-targeted therapies offer new hope for patients with aggressive neuroendocrine malignancies that have historically poor prognoses.